Tuesday, March 31 – 1:00 – 2:00 pm ET Register The promise of real-world data is driving increased requirements and use. But, what does high-quality RWD actually look like? How should life sciences companies access and use it most effectively? What are the implications when applying RWD to clinical trials, registries, and other evidence and[…]
Published February 28, 2020, HealthEconomics.com – written by Kathryn Starzyk, Senior Director, RWE, OM1 Technological innovations have fostered the age of big data in healthcare – and the huge populations amassed afford the ability to mine for key subpopulations — getting down to ever more precise groups of likely responders to therapy, high-risk patients and[…]
Published by TechCrunch, December 17 2019, written by Jonathan Shieber OM1, a big-data analytics company for the healthcare industry, has raised $50 million in its latest round of financing to expand its sales and marketing and product development activities as it brings clinical insights to hospitals and big pharma companies alike. The new financing highlights[…]
Wednesday, August 14, 2019 Being able to quickly and cost-effectively collect, analyze, and share real-world evidence on a treatment is critical to improving outcomes in rheumatology conditions. Fortunately, advances in data linkage and processing capabilities are enabling greater access to patient journeys via deep, linked clinical data. At the same time, new tools are empowering[…]
New Project Puts Standardized Outcomes Measures for Depression into Real-World Use, from Registries to the Clinic OM1 partners with AHRQ, ABFM, APA and others to implement BOSTON, July 17, 2019 —OM1, a leading health outcomes and technology company, today announced it is has been awarded the CAPSTONE – Outcome Measure Harmonization and Data Infrastructure for[…]
